DAGCO Inc’s Pacific Biosciences PACB Stock Holding History

DAGCO Inc’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,678	Closed	-$16.5K	–	338
2023 Q4	$16.5K	Buy	+1,678	New	+$13.7K	0.02%	181

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

DAGCO Inc's PACB Position: Q1 2024 in Review

DAGCO Inc sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 1,678 shares — an estimated $16.5K sold.

DAGCO Inc first reported a position in PACB in Q4 2023 and held it in 1 quarter. The position peaked at $16.5K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

DAGCO Inc reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
DAGCO Inc sold 1,678 Pacific Biosciences shares in Q1 2024, an estimated $16.5K.
DAGCO Inc first reported a position in Pacific Biosciences in Q4 2023 and held it in 1 quarter.
DAGCO Inc's Pacific Biosciences position peaked at $16.5K in Q4 2023.
268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.